“Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
Cardiol Therapeutics (NASDAQ: CRDL) presented breakthrough Phase II MAvERIC-Pilot data at the American Heart Association (AHA) Scientific Sessions 2024, showcasing CardiolRx™ as a potential game-changer for recurrent pericarditis treatment. The…
